Naz Rahman
Stock Analyst at Maxim Group
(0.23)
# 4,304
Out of 4,981 analysts
37
Total ratings
16.13%
Success rate
-43.36%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCPH scPharmaceuticals | Downgrades: Hold | n/a | $5.63 | - | 4 | Aug 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.51 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.17 | +175.75% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $4.07 | +1,742.75% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $24.81 | +182.14% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.22 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.96 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.60 | +1,237.79% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.42 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.81 | +268.87% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.50 | +1,766.67% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $394.53 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.19 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $2.36 | +111.86% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.41 | +148.96% | 1 | Feb 25, 2022 |
scPharmaceuticals
Aug 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $5.63
Upside: -
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.51
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.17
Upside: +175.75%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $4.07
Upside: +1,742.75%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $24.81
Upside: +182.14%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.22
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.96
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.60
Upside: +1,237.79%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.42
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.81
Upside: +268.87%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.50
Upside: +1,766.67%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $394.53
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.19
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $2.36
Upside: +111.86%
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.41
Upside: +148.96%